Literature DB >> 11922761

Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.

Matthias Lechmann1, Elisabeth Kremmer, Heinrich Sticht, Alexander Steinkasserer.   

Abstract

CD83 is a 45-kDa glycoprotein and member of the immunoglobulin (Ig) superfamily. It is the best known marker for mature dendritic cells. Although the precise function of CD83 is not known, its selective expression and upregulation together with the costimulators CD80 and CD86 suggests an important role of CD83 in the induction of immune responses. To perform functional studies and to elucidate its mode of action it is vital to obtain recombinant expressed and highly purified CD83 molecules. Therefore, the external Ig domain of human CD83 (hCD83ext) was expressed as a GST fusion protein (GST-hCD83ext) and the soluble protein was purified under native conditions. The fusion protein was purified using GSTrap columns followed by anion-exchange chromatography. GST-hCD83ext was then cleaved using thrombin and soluble hCD83ext was further purified using GSTrap columns and finally by a preparative gel filtration as a polishing step and used for further characterization. The purified GST-hCD83 fusion protein was also used to generate monoclonal anti-CD83 antibodies in a rat system. Two different monoclonal antibodies were generated. Using these antibodies, CD83 was specifically recognized in FACS and Western blot analyses. Furthermore, we showed that native CD83 is glycosylated and that this glycosylation influences the binding of the antibodies in Western blot analyses. Finally, the purified hCD83ext protein was analyzed by one-dimensional NMR and these analyses strongly indicate that hCD83ext is folded and could therefore be used for further structural and functional studies. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11922761     DOI: 10.1006/prep.2001.1594

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

Review 1.  Dendritic cell CD83: a therapeutic target or innocent bystander?

Authors:  Charlene M Prazma; Thomas F Tedder
Journal:  Immunol Lett       Date:  2007-10-29       Impact factor: 3.685

2.  Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.

Authors:  Joe M Horvatinovich; Elizabeth W Grogan; Marcus Norris; Alexander Steinkasserer; Henrique Lemos; Andrew L Mellor; Irina Y Tcherepanova; Charles A Nicolette; Mark A DeBenedette
Journal:  J Immunol       Date:  2017-02-13       Impact factor: 5.422

3.  The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo.

Authors:  Matthias Lechmann; Naomi Shuman; Andrew Wakeham; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

4.  Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83.

Authors:  Elisabeth Zinser; Matthias Lechmann; Antje Golka; Manfred B Lutz; Alexander Steinkasserer
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

5.  Targeting CD83 for the treatment of graft-versus-host disease.

Authors:  Xiongfei Wang; Ming Q Wei; Xiaosong Liu
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

6.  Herpes simplex virus type 1 induces CD83 degradation in mature dendritic cells with immediate-early kinetics via the cellular proteasome.

Authors:  Mirko Kummer; Nadine M Turza; Petra Muhl-Zurbes; Matthias Lechmann; Chris Boutell; Robert S Coffin; Roger D Everett; Alexander Steinkasserer; Alexander T Prechtel
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

7.  The expression and characterization of functionally active soluble CD83 by Pichia pastoris using high-density fermentation.

Authors:  Yugang Guo; Rui Li; Xiaoping Song; Yongjun Zhong; Chenguang Wang; Hao Jia; Lidan Wu; Dong Wang; Fang Fang; Jiajia Ma; Wenyao Kang; Jie Sun; Zhigang Tian; Weihua Xiao
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.